Strides Pharma awaiting govt nod for Favipiravir, says CEO R Ananthanarayanan

"Our focus is ensuring that we are able to get approvals for all the necessary studies and data in India. We will be able to provide the drug once the Indian approvals come through. This is our main bottleneck now," said R Ananthanarayanan.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2VMnkW5
via IFTTT